The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes

@article{Smith2017TheII,
  title={The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes},
  author={Stacy V. Smith and Deborah I Friedman},
  journal={Headache: The Journal of Head and Face Pain},
  year={2017},
  volume={57}
}
The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) was the first large, randomized study on the use of acetazolamide and weight loss for treatment of idiopathic intracranial hypertension‐associated vision loss. The multicenter trial also examined a number of secondary outcomes. This review summarizes all available results of the study published in the literature since 2014. 
Idiopathic Intracranial Hypertension: The Monster Within
TLDR
In this article, the common problems encountered while dealing with patients of IIH are reviewed and a comprehensive update on different aspects of IIh is provided. Expand
Updates on Recent Developments in Idiopathic Intracranial Hypertension
Idiopathic intracranial hypertension (IIH) or pseudotumor cerebri syndrome (PTCS) is a condition in which the intracranial pressure is increased without radiographic or laboratory evidence ofExpand
Pediatric Intracranial Hypertension: a Current Literature Review
TLDR
Pediatric intracranial hypertension is a disorder that if left untreated can lead to poor quality of life and morbidity, but adult data suggests acetazolamide remains an acceptable first-line medication. Expand
An update of idiopathic intracranial hypertension
TLDR
This review provides a comprehensive and updated review on idiopathic intracranial hypertension, including the most current studies and treatment options, and special focus is put on recent theories about the pathophysiology, and on newer prospective studies on treatment modalities. Expand
Management of idiopathic intracranial hypertension in pregnancy
TLDR
The case of a 33-year-old woman with progressive visual loss and intractable headache from 20 weeks’ gestation requiring ventriculoperitoneal shunting during pregnancy is reported. Expand
Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes
TLDR
This review attempts to identify DIIH-associated drugs based on a strict diagnostic and drug-causality algorithm, then stratify them into appropriate risks categories to assist dermatologists and other physicians with patient education and monitoring of symptoms of secondary intracranial hypertension. Expand
Idiopathic Intracranial Hypertension and Multiple Sclerosis Overlap
TLDR
A 33-year-old morbidly obese woman who developed progressive worsening blurry vision and unilateral temporal headache was found to have papilledema which prompted workup for intracranial hypertension and findings were suggestive of a demyelinating process such as MS in addition to IIH. Expand
Intracranial hypertension: a current review
TLDR
The recent completion of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) has provided a wealth of data with regards to adult intracranial hypertension, which will hopefully assist with management in the pediatric population. Expand
Management of Idiopathic Intracranial Hypertension: Experience of a North African Center
TLDR
The IIH is predominantly a disease of women in the childbearing age; surgical treatment is a good option for patients who resisted medication or did not tolerate it as well as for ICH fulminous in emergency cases. Expand
Role of Adjunct Treatments for Idiopathic CSF Leaks After Endoscopic Repair
TLDR
The results in a patient cohort in which only symptomatic patients are subjected to further testing and treatment are reported, indicating the need for routine use of intracranial pressure‐lowering adjunct treatments after endoscopic repair. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial
To characterize the phenotype, headache‐related disability, medical co‐morbidities, use of symptomatic headache medications, and headache response to study interventions in the IdiopathicExpand
The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK
TLDR
This study identified the incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK and found that middle-aged women with a history of high blood pressure were at higher risk of IIH. Expand
The Idiopathic Intracranial Hypertension Treatment Trial: Design Considerations and Methods
  • D. Friedman, M. Mcdermott, +7 authors M. Wall
  • Medicine
  • Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2014
TLDR
The IIHTT is the first randomized, double-masked placebo-controlled trial to study the effectiveness of medical treatment for patients with IIH and is described as a first-of-its-kind trial. Expand
Diagnostic criteria for idiopathic intracranial hypertension
TLDR
New diagnostic criteria for IIH are described that may be used for routine patient management and for research purposes and not addressed in the Modified Dandy Criteria. Expand
The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.
TLDR
The data show that IIH is almost exclusively a disease of obese young women and quality of life measures, including the National Eye Institute Visual Function Questionnaire-25 and the Short Form-36 physical and mental health summary scales, were lower compared with population norms. Expand
The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)
TLDR
Almost 6% weight loss was associated with resolution of marked papilledema in these authors' patients, and the benefit of acetazolamide in IIH is questioned since weight loss appeared to have been the catalyst for reducing the severity of papillema. Expand
Effects of weight loss on the course of idiopathic intracranial hypertension in women
TLDR
Weight reduction is associated with more rapid recovery of both papilledema and visual field dysfunction in patients with IIH compared with those who do not lose weight. Expand
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
TLDR
Whether acetazolamide is beneficial in improving vision when added to a low-sodium weight reduction diet in patients with IIH and mild visual loss is investigated to establish an evidence base for its use. Expand
Idiopathic intracranial hypertension. A prospective study of 50 patients.
TLDR
Monitoring of newly-diagnosed patients with idiopathic intracranial hypertension over a period of 2 to 39 months found visual loss in patients with IIH is common and is often reversible, and improvement of visual field grade was significantly associated only with weight gain during the year before diagnosis. Expand
Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial
TLDR
The majority of participants in the Idiopathic Intracranial Hypertension Treatment Trial were able to tolerate acetazolamide above 1 g/d for 6 months and appears to have an acceptable safety profile at dosages up to 4 g/D in the treatment of idiopathics intracranial hypertension. Expand
...
1
2
3
4
...